IVABRADINE AND DIASTOLIC HEART FAILURE  by De Masi De Luca, Gabriele
Heart Failure
E1009
JACC March 27, 2012
Volume 59, Issue 13
IVABRADINE AND DIASTOLIC HEART FAILURE 
ACC Moderated Poster Contributions
McCormick Place South, Hall A
Monday, March 26, 2012, 11:00 a.m.-Noon
Session Title: Unraveling Heart Failure with Preserved Ejection Fraction
Abstract Category: 13. Heart Failure: Therapy
Presentation Number: 1222-424
Authors: Gabriele De Masi De Luca, Card. Panico Hospital, Tricase (Lecce), Italy
Background: Heart failure with normal ejection fraction (HFNEF) is present in about 50% of all CHF patients and mortality is similarly compared 
to patients with heart failure and reduced EF. Up to date, there is no evidence for a treatment available for improving outcome in HFNEF patients. 
High heart rates might be detrimental for HFNEF patients with diastolic dysfunction, since this will further limit LV filling. The purpose of this study is 
to investigate if the addition of ivabradine to optimal medical treatment might be of benefit in this patients subset in terms of diastolic function and 
exercise capacity improvement.
Methods: 111 pts (30%female, mean age 59±14yrs) with HFNEF, NYHA II/IV and EF≥50%, with optimal medical treatment, were randomized to two 
groups in order to receive ivabradine 5mg uptitrated to 7.5mg bid (IVA-Group, n=53) or placebo (P-Group, n=58). Clinical examination (NYHAclass), 
cardiopulmonary test (pVO2, exercise duration ED) and echocardiographic evaluation of diastolic function, E/Em (at LV lateral mitral annulus 
transmitral) E-wave deceleration time (EDT), index of left atrial volumes and EF (LAVI and LAEF), IVRT, were performed at baseline and after 2 months.
Results: After 2 months, resting HR was decreased significantly in IVA-Group compared to P-Group (IVA-G b/min 83.2±5.2 vs 67.4±3.1, P-G 
81.3±2.9 vs 80.4±2.0, P<0.05). Exercise capacity was significantly improved by ivabradine (ED-IVA min 5,9±2.4 vs 7.2±2.9, P<0.05; PVO2-IVA ml/
Kg/min 16.1±2.8 vs 19.3±3.3 P<0.05) but not by placebo (PVO2-P 15.7±3.1/16.0±2.3 p=n.s). Concerning to echocardiographic evaluation, LAVI 
and LAEF did not differ between subgroups, while concerning to EDT, IVRT, E/Em we can observe a meaningful difference between basal and Fup 
for the group IVA but not for the placebo group (EDT ms IVA-G 260±15 vs 248±15 p<0.02; IVRT ms IVA-G 89±6 vs 74±11, p<0.05; E/Em IVA-G 
11.9±2.1 vs 9.5±1,4; p<0,05).
Conclusions: Thus the data of our study indicate that the addition of Ivabradine to optimal medical treatment for the HFNF improves diastolic 
function and exercise capacity.
